Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2024; 16(9): 1206-1210
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1206
Kick-start for metabolomics in liver disease
Armando Guerra-Ruiz
Armando Guerra-Ruiz, Laboratory Medicine, University Hospital Marques de Valdecilla, Santander 39008, Cantabria, Spain
Armando Guerra-Ruiz, Commission on Biochemical Assessment of Liver Disease, Spanish Society of Clinical Chemistry (SEQC-ML), Barcelona 08025, Catalonia, Spain
Armando Guerra-Ruiz, Digestive Diseases, Valdecilla Research Institute (IDIVAL), Santander 39011, Cantabria, Spain
Author contributions: As the sole author, Guerra-Ruiz A was responsible for all aspects of the work, including conception, design, research, writing, and finalization of the manuscript. No external contributions or assistance were involved in the preparation of this editorial.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Armando Guerra-Ruiz, PhD, Consultant Physician-Scientist, Laboratory Medicine, University Hospital Marques de Valdecilla, Avda Valdecilla s/n, Santander 39008, Cantabria, Spain. r-gruiz@hotmail.com
Received: May 18, 2024
Revised: July 12, 2024
Accepted: July 17, 2024
Published online: September 27, 2024
Processing time: 128 Days and 9.4 Hours
Core Tip

Core Tip: This editorial explores the transformative potential of metabolomics in liver disease research and management. Highlighting four key studies, we explore how metabolomics aids in biomarker discovery, reveals altered biochemical pathways, supports personalized medicine, and elucidates disease mechanisms. By integrating metabolomics in clinical practice, we can enhance early diagnosis, optimize treatment strategies, and develop targeted therapies, ultimately improving patient outcomes. This comprehensive approach underscores the versatility and importance of metabolomics in advancing precision medicine for liver diseases.